CD133(+) circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients

BACKGROUND: Blood-based biomarkers may be particularly useful for patient selection and prediction of treatment response for angiogenesis inhibitors. Circulating endothelial cells (CECs) and haematopoietic progenitor cells (HPCs) might have a role in tumour angiogenesis and in tumour growth. Measure...

Descripción completa

Detalles Bibliográficos
Autores principales: Vroling, L, Lind, J S W, de Haas, R R, Verheul, H M W, van Hinsbergh, V W M, Broxterman, H J, Smit, E F
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2816651/
https://www.ncbi.nlm.nih.gov/pubmed/20010948
http://dx.doi.org/10.1038/sj.bjc.6605477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2816651/
https://www.ncbi.nlm.nih.gov/pubmed/20010948
http://dx.doi.org/10.1038/sj.bjc.6605477

Ejemplares similares